subsequent administrations proceed every 3 weeks). Treatment continues until the subject experiences intolerance, withdraws informed consent, or disease progression occurs, at which point administrati
Sponsors
Guangdong Provincial People's Hospital
Conditions
Driver Gene-negative Lung Cancer Complicated by Brain and/or Leptomeningeal MetastasesTriple-Negative Breast Cancer with Brain Metastases
Phase 1
A Phase I Dose-Escalation and Dose-Expansion Clinical Study Evaluating the Tolerability, Safety, Pharmacokinetics , and Efficacy of MT027 Cell Injection in Patients with Triple-Negative Breast Cancer and Brain Metastases
Active, not recruitingChiCTR2600116792
Start: 2026-01-20Updated: 2026-01-27
A Dose-escalation and Dose-expansion Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile, and Efficacy of MT027 Cell Injection in Patients with Lung Cancer Complicated by Brain and/or Leptomeningeal Metastases
Active, not recruitingChiCTR2600116919
Start: 2026-01-30Updated: 2026-01-27